Dassault Systemes Pursues Acquisition of ArisGlobal to Build Integrated AI Intelligence Platform for Life Sciences

Dassault Systemes is pushing ahead with the acquisition of ArisGlobal as it seeks to strengthen its AI capabilities in the life sciences sector. The deal aligns with its vision of building an integrated AI platform spanning drug development, regulatory management and real-world evidence management.

Dassault Systemes signed the final acquisition agreement for ArisGlobal on the 23rd in Velizy-Villacoublay, France, local time. The deal received unanimous approval from the Dassault Systemes board.

Dassault Systemes plans to pay about USD 1.8 billion in cash at closing of the transaction. The agreement also includes a condition under which it would pay up to USD 200 million more if AI-related revenue targets are met over the coming years.

ArisGlobal has an AI-native enterprise compliance platform. Its customers include half of the world's top 50 biopharmaceutical companies, as well as more than 200 clients across biotechnology, medical devices, CROs and global health authorities. ArisGlobal's platform processes more than 12 million patient safety reports a year.

Dassault Systemes described the compliance market that ArisGlobal operates in as a high-growth area. It said ArisGlobal's business areas are continuing to grow at a double-digit pace and that the market is projected to reach USD 7.5 billion in 2030.

Based on that view, Dassault Systemes is moving ahead with the acquisition in a way that combines its own expertise in drug discovery, clinical trials, manufacturing and quality with ArisGlobal's capabilities in regulatory operations and real-world evidence (RWE) management. After the acquisition, the company plans to build a continuous evidence loop that continuously connects and uses data across the entire therapeutic lifecycle, and to provide an integrated data and intelligence platform.

Dassault Systemes said it expects the acquisition to create revenue synergies for both companies. It also said ArisGlobal has profitability at a level similar to Dassault Systemes, and based on that, it expects the deal to contribute to Dassault Systemes' revenue growth rate and earnings per share (EPS) starting in the first year after the acquisition.

The acquisition will be financed entirely with cash held by Dassault Systemes, and its financial flexibility is expected to remain intact after the transaction.

The transaction is subject to regulatory approvals and the satisfaction of customary closing conditions, and is expected to close in the second half of 2026.

Pascal Daloz said the acquisition is an important milestone in the Dassault Systemes vision. That vision is to transform the life sciences industry by linking therapeutic outcomes across molecules, patients and real-world settings. He added that the life sciences industry is entering a new era of innovation driven by AI and precision medicine, while operational complexity and regulatory requirements are also increasing. Amaan Wasan also said the life sciences industry has reached a fundamental inflection point. He said the foundation of the future is not better software but connected intelligence, and explained that the current data landscape is fragmented. He added that the combination with Dassault Systemes would make it possible to integrate data across research and development and regulatory operations, enabling a comprehensive AI-first intelligence platform and faster delivery of better patient outcomes.

Source: IT DAILY · Yang Seung-gap
Original: https://www.itdaily.kr/news/articleView.html?idxno=241339

References

• https://www.itdaily.kr/news/articleView.html?idxno=241339